This clinical trial is focused on studying the effects of a medication called Guselkumab on individuals with a condition known as Psoriatic Arthritis, specifically targeting those with active axial disease. Psoriatic Arthritis is a type of arthritis that affects some people who have psoriasis, a condition that features red patches of skin topped with silvery scales. Axial disease refers to inflammation in the spine and the joints that connect the spine to the pelvis. The medication being tested, Guselkumab, is administered as an injection and is being compared to a placebo to evaluate its effectiveness and safety.

The purpose of this study is to assess how well Guselkumab can reduce symptoms related to the axial part of Psoriatic Arthritis. Participants in the study will receive either Guselkumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will follow participants over a period of time to observe changes in their symptoms and overall health. The main focus will be on the reduction of symptoms such as spinal pain and inflammation, which are common in individuals with this condition.

Throughout the study, participants will be monitored to ensure their safety and to gather data on the effectiveness of the treatment. The study aims to provide valuable information on whether Guselkumab can be a beneficial treatment option for those suffering from Psoriatic Arthritis with axial involvement. This research is important as it seeks to improve the quality of life for individuals affected by this chronic condition.